By Laurie Chen SHANGHAI, July 23 (Reuters) - Hong Kong-listed Insilico Medicine has cut drug development timelines to about one year by combining AI with its China research ecosystem, its CEO said, ...
-
-
Recent Updates
- AI shortens drug discovery to around 1 year in China, Insilico CEO says
- Zhibao Technology’s Plans to Acquire 3,500 Bitcoin in Nasdaq PIPE Financing Deal
- Chip firm priced as China’s most valuable company before its IPO brings scrutiny to crypto platform
- Global youth find common ground in Shanghai
- Ready to deploy: China sends strong AI message to US
- After tackling discounts in China, Nike still needs to win back shoppers
- After tackling discounts in China, Nike still needs to win back shoppers
- Volkswagen’s China Strategy Embraces Self-Driving Future
- US Defense Initiates Compliance Shift with New Rare Earth Metal Supplier
- Chinese Optical Parts Maker Zhongji Innolight Seeks Record IPO in Hong Kong
Blogroll